Information Warfare Consortium Adds 26 New Members
Published Date: 6/22/2026
Notice
Summary
The Information Warfare Research Project Consortium just updated its team by adding 26 new members and saying goodbye to 9 others. This change helps protect members from big antitrust lawsuits, limiting damages to actual losses. If you’re part of this tech and defense group, keep an eye out for more updates as membership stays open and active.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Antitrust Damage Limit Extended to Consortium
If you are a member of the Information Warfare Research Project Consortium (IWRP Consortium), the Department of Justice received notifications on April 2, 2026 that extend the National Cooperative Research and Production Act's protection limiting antitrust plaintiffs to recover only actual damages in specified circumstances. The notice also records that 26 parties were added and 9 parties withdrew, and it says membership remains open.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19100, United States of America, et al. v. RealPage, Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government is stopping Pinnacle Property Management from using RealPage’s pricing software that shares sensitive info with landlords, which broke competition rules. Pinnacle must also set up new rules to keep things fair and help the government watch over this. People have 60 days to share their thoughts before the court makes it official.
2026-18136, United States v. KKR & Co. Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
The U.S. government caught KKR & Co. Inc. for not properly reporting important business deals before they happened—16 times! Now, KKR has to pay a huge $250 million fine within 30 days to settle the case. This action helps keep big business honest and fair for everyone.
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Tennessee are stopping APAC-Tennessee from buying Standard Construction Group because it could hurt competition. To fix this, both companies must sell two key facilities in Memphis and Millington, Tennessee. People have 60 days to share their thoughts before the deal is finalized, keeping the market fair and open.
2026-16112, United States et al. v. Cal-Maine Foods, Inc. et al.; Proposed Final Judgment and Competitive Impact Statement
2026-14935, United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
The U.S. government says Edwards LifeSciences broke the rules when it bought JC Medical from Genesis MedTech. Edwards must pay $10 million, Genesis pays $2 million, and Edwards has to get approval before buying any company working on special heart valve devices in the U.S. This keeps the market fair and protects competition in heart health tech.
2026-14903, United States, et al. v. OhioHealth Corporation; Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Ohio are taking on OhioHealth Corporation for using sneaky contract rules that stop insurers from offering cheaper health plans. OhioHealth must now remove these rules and promise not to use them again, helping more budget-friendly options reach patients. People have 60 days to share their thoughts before the court makes it official.
Previous / Next Documents
Previous: 2026-12365, Notice Pursuant to the National Cooperative Research and Production Act of 1993-ASTM International
ASTM International has updated its list of ongoing projects that help set important standards, and they’ve told the government about these changes to keep antitrust rules fair. This update affects companies and groups involved in creating these standards, ensuring any legal claims about competition are limited to actual damages. The new list covers work started between December 2025 and February 2026, with details available online—no extra costs or deadlines for the public right now.
Next: 2026-12367, Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.